Hypotrichosis 8 (HYPT8) Cell Models for Research

Hypotrichosis 8 (HYPT8) is a rare genetic disorder characterized by progressive hair loss, typically beginning in childhood. The exact prevalence is unknown, but it is estimated to affect less than 1 in 1,000,000 individuals worldwide (WHO, 2024). The condition is inherited in an autosomal recessive manner and is caused by mutations in the LIPH gene. Clinical impact includes sparse hair on the scalp, which may progress to complete baldness by early adulthood. There is no cure, and current treatments are limited to cosmetic interventions. The rarity of the disease underscores the need for research into its molecular mechanisms and potential therapeutic targets.

HYPT8 serves as an excellent model for studying hair follicle biology and the molecular pathways involved in hair growth and cycling. The disease is monogenic, making it amenable to gene editing and functional studies. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project, provide expression data for LIPH and related genes in various tissues. Open questions include the precise role of LIPH in hair follicle development and the potential for targeted therapies to restore hair growth. Gene-edited cell models are valuable tools for investigating these questions.

• • Although HYPT8 is not a cancer, the molecular pathways involved are relevant to cell signaling and proliferation. The primary pathway is the phospholipase signaling pathway, which is crucial for hair follicle development. Key steps include:
• • LIPH encodes a phospholipase that produces lysophosphatidic acid (LPA) from phosphatidic acid.
• • LPA binds to the receptor P2RY5 (also known as LPAR6), activating downstream signaling cascades.
• • This signaling is essential for the proper development and cycling of hair follicles.
• • Mutations in LIPH disrupt this pathway, leading to impaired hair growth.

Data from ClinVar and COSMIC indicate that LIPH mutations are the primary cause of HYPT8, with over 20 pathogenic variants reported.

• • The LIPH/P2RY5 signaling pathway is the central network disrupted in HYPT8. Key nodes include:
• • LIPH: enzyme producing LPA.
• • P2RY5: G-protein coupled receptor for LPA.
• • Downstream effectors: activation of Rho GTPases, which regulate actin cytoskeleton and cell migration.
• • Other pathways: cross-talk with Wnt and Hedgehog signaling, which are also important for hair follicle development.

Dysregulation of these networks leads to abnormal hair follicle morphogenesis and cycling.

Organoids derived from hair follicle stem cells can recapitulate hair follicle development and are useful for studying LIPH function in a 3D context.

• • Genetically engineered mouse models (GEMMs) with Liph knockout have been generated and show hair loss phenotypes.
• • Induced models using CRISPR/Cas9 in mice can create specific Liph mutations.
• • Patient-derived xenografts (PDX) are less common due to the non-cancerous nature of the disease, but skin grafts from patients can be used.
• • Zebrafish models with liph mutations are also available for high-throughput screening.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise LIPH mutations. For example, a LIPH knockout cell line can be generated in HEK293 or HaCaT cells to study the loss-of-function effects. Alternatively, knock-in lines with specific patient mutations (e.g., c.742C>T, p.Arg248Ter) can be created to model the disease. These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for drug screening and functional studies.

Knockout and knock-in lines are used to validate the role of LIPH in hair follicle biology. For example, LIPH knockout cells show reduced LPA production and altered expression of downstream targets. These models help identify novel interacting partners and signaling pathways.

Isogenic pairs (wild-type vs. LIPH mutant) can be used in high-throughput screens to identify compounds that rescue the mutant phenotype. This is particularly useful for developing therapies that bypass the defective LIPH enzyme. Resistance modeling is less relevant for a genetic hair loss disorder, but the approach can be adapted to study compensatory mechanisms.

CRISPR-based synthetic lethality screens can identify genes that are essential in LIPH-mutant cells but not in wild-type cells. These genes may serve as potential drug targets or biomarkers for disease progression. For example, screening a genome-wide CRISPR library in LIPH knockout cells could reveal dependencies that could be exploited therapeutically.